Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Incidence of Pneumocystis jirovecii pneumonia utilizing a polymerase chain reaction‐based diagnosis in patients receiving bendamustine

Cancer Medicine(2021)10.1002/cam4.4067Source: DataRank Database

Incidence of Pneumocystis jirovecii pneumonia utilizing a polymerase chain reaction‐based diagnosis in patients receiving bendamustine is a research paper published in Cancer Medicine (2021). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)OA: goldTopics (50)IDs (PubMed, PMC)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Jason N. Barreto ORCID,Carrie A. Thompson ORCID,Kristin C. Mara ORCID,Pritish K. Tosh ORCID,Andrew H. Limper ORCID

Live enrichment

PubMed:34155819 PMC:PMC8335812

National Institutes of Health

Grant: R01‐HL62150

NHLBI NIH HHS

Grant: R01 HL062150

NCATS NIH HHS

Grant: TL1 TR002380

National Institutes of Health

Grant: 5TL1TR002380-07

Mayo Clinic Center for Clinical and Translational Science (CCaTS)

National Institutes of Health

Grant: 4R01HL062150-24

Pneumocystis carinii: Macrophage & Epithelial Activation

goldLicense: cc-by

publisherhttps://doi.org/10.1002/cam4.4067

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4067

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/cam4.4067

repositoryhttps://doaj.org/article/659c1499f6e148ddaff8752a4d3f6d56

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8335812

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

HumansPneumocystis cariniiPneumonia, PneumocystisLymphoma, FollicularAntineoplastic Agents, AlkylatingAntifungal AgentsIncidenceProportional Hazards ModelsRetrospective StudiesPolymerase Chain ReactionTime FactorsAdultAgedAged, 80 and overMiddle AgedFemaleMaleYoung AdultBendamustine HydrochlorideRituximabAntineoplastic Agents, Immunological

Keywords

ChemotherapyLymphomaClinical ManagementHematological CancerAdultMaleAntifungal AgentsTime FactorsPneumocystis cariniiPolymerase Chain ReactionAntineoplastic Agents, ImmunologicalBendamustine HydrochlorideHumansAntineoplastic Agents, AlkylatingLymphoma, FollicularRC254-282AgedProportional Hazards ModelsRetrospective StudiesAged, 80 and overIncidencePneumonia, PneumocystisNeoplasms. Tumors. Oncology. Including cancer and carcinogensClinical Cancer ResearchMiddle AgedFemaleRituximab

Sustainable Development Goals

SDG 3: 3. Good health